SIRT5 Attenuates Doxorubicin-Induced Acute Cardiac Injury by Modulating PHB2 Succinylation and the Mitophagic

Aihui Zeng1,2,3, Haiqiong Liu1,3, Xudong Song1,3

  • 1Department of Cardiology, Heart Center, Zhujiang Hospital, Southern Medical University, NO. 253, Gongye Avenue, Guangzhou, 510282, Guangdong, People's Republic of China.

Insights

Sirtuin 5 (SIRT5) protects against doxorubicin-induced cardiac injury by regulating prohibitin 2 (PHB2) succinylation and mitophagy. This highlights the SIRT5-PHB2 axis as a therapeutic target for chemotherapy-related heart damage.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Medicine
  • Oncology Therapeutics

Background:

  • Doxorubicin (DOX) chemotherapy causes cardiotoxicity, linked to mitochondrial dysfunction and impaired mitophagy.
  • Sirtuin 5 (SIRT5), a mitochondrial protein, is involved in homeostasis, but its role in DOX cardiotoxicity is unclear.

Purpose of the Study:

  • To investigate if SIRT5 mitigates acute DOX-induced cardiac injury.
  • To explore SIRT5's regulation of prohibitin 2 (PHB2) succinylation and mitochondrial quality control.

Main Methods:

  • Established a DOX-induced cardiotoxicity mouse model and used primary cardiomyocytes.
  • Analyzed serum biomarkers (LDH, cTnT, CK-MB), oxidative stress (ROS), apoptosis, and mitophagy.
  • Investigated PHB2 succinylation via immunoprecipitation and immunoblotting; assessed SIRT5-PHB2 interaction.

Main Results:

  • DOX elevated cardiac injury markers and reduced SIRT5 expression.
  • DOX induced ROS and apoptosis, with altered mitophagy signaling, which SIRT5 overexpression attenuated.
  • DOX increased PHB2 succinylation; SIRT5 overexpression reduced it and showed colocalization/interaction with PHB2.

Conclusions:

  • SIRT5 attenuates acute DOX-induced cardiotoxicity.
  • The SIRT5-PHB2 axis modulates PHB2 succinylation and mitophagy, offering a potential therapeutic target for early-onset DOX cardiotoxicity.